Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

Crestone Pharmaceuticals recently shared topline results from a phase 2 trial of its investigational drug treatment for ...

The investigational new drug application for VNX-101, a gene therapy aimed at treating CD19-positive acute lymphoblastic ...

Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on Biohaven Ltd. (BHVN – Research Report). The associated price ...

Shares of Wockhardt are locked at upper circuit after the pharma company said on September 19 that one of its investigational drug - Zaynich - has successfully treated critically ill patients of ...

Many investors and prognosticators think one investigational drug in particular has vast potential ... who early Thursday morning published a new research note on the now-prominent biotech. Ulz is ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha ...